Millennium Management’s Windtree Therapeutics WINT Stock Holding History

Millennium Management’s Portfolio WINT Stock Details WINT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10	Closed	-$1K	–	7554
2021 Q4	$1K	Hold	10	–	–	﹤0.01%	6691
2021 Q3	$2K	Hold	10	–	–	﹤0.01%	6709
2021 Q2	$3K	Hold	10	–	–	﹤0.01%	6451
2021 Q1	$3K	Hold	10	–	–	﹤0.01%	5831
2020 Q4	$2.31M	Buy	+10	New	+$2.77M	﹤0.01%	3126

Other funds holding WINT

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Gradient Investments Arden Hills, Minnesota $7.25B AUM 20.71% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Millennium Management's WINT Position: Q1 2023 in Review

Millennium Management sold out of Windtree Therapeutics (WINT) in Q1 2023, closing a stake of 2 shares — an estimated $14K sold.

Millennium Management first reported a position in WINT in Q3 2020 and held it in 6 quarters. The position peaked at $552K in Q4 2020. 2 funds tracked by Wall St. Rank hold WINT as of Q1 2023.

Millennium Management reported no remaining Windtree Therapeutics position as of Q1 2023 after selling out during the quarter.
Millennium Management sold 2 Windtree Therapeutics shares in Q1 2023, an estimated $14K.
Millennium Management first reported a position in Windtree Therapeutics in Q3 2020 and held it in 6 quarters.
Millennium Management's Windtree Therapeutics position peaked at $552K in Q4 2020.
2 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q1 2023.

Based on Millennium Management's 13F filing for Q1 2023, filed 15 May 2023.